BioSpace News Archive

Eledon Pharmaceuticals, a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis, announced that it plans to release financial results for the first quarter ended March 31, 2021 on Thursday, May 13, after the close of trading.

4D Molecular Therapeutics announced a new collaboration with investigators at the University of California, Berkeley focused on expanding the vector invention power of 4DMT’s Therapeutic Vector Evolution platform by applying machine learning technology to the AAV vector capsid datasets generated from 4DMT’s platform.

Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, announced that the company will participate at the BofA Securities 2021 Virtual Health Care Conference.

More than 30 million Americans at risk for Lyme disease exposure, which can result in severe neurological and other debilitating symptoms

Xenon Pharmaceuticals Inc., a clinical stage biopharmaceutical company, announced it will report its first quarter 2021 financial and operating results after the close of U.S. financial markets on Tuesday, May 11, 2021.

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, May 11, 2021, at 8:00 a.m. ET to review its first quarter 2021 financial results and provide an update on the company.

Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission in patients with autoimmune (‘1805 a protein drug) and allergic disease (‘1104 a peptide drug), announced today positive data from a multiple ascending dose (MAD) Phase 1 clinical trial evaluating the safety and tolerability of ‘1104, a first-in-class peptide for the treatment of allergic disease

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its fourth fiscal quarter and fiscal year 2020, ended March 31, 2021. The webcast and conference call will be held at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on May 11, 2021.